Indevus saw its shares bounce higher this morning after researchers announced that a mid-stage trial of its experimental therapy pagoclone for stuttering demonstrated statistically significantly responses in two out of three patient evaluations. Researchers evaluated 132 subjects in the study, with about two thirds receiving pagoclone. There is currently no approved drug for stuttering.
- here's the AP report on the trial data